The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial.
Tejaswini KulkarniChad A NewtonSachin GuptaKaterina SamaraElana J BernsteinPublished in: Pulmonary therapy (2024)
ClinicalTrials.gov identifier, NCT01366209.